Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 1 · 25%

IVIg vs intravenous methylprednisolone

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 1.46 [0.4, 5.38]
1 study · 45 participants
Moderate

IVIg vs placebo

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 2.4 [1.72, 3.36]
5 studies · 269 participants
High

IVIg vs plasma exchange

Significant improvement in disability within 6 weeks · people with CIDP

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs prednisolone

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 0.91 [0.5, 1.68]
1 study · 29 participants
Moderate